Keebeck Wealth Management Acquires New Holdings in Natera, Inc. $NTRA

Keebeck Wealth Management purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, HoldingsChannel.com reports. The fund purchased 8,241 shares of the medical research company’s stock, valued at approximately $2,237,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Natera in the second quarter valued at about $2,962,770,000. Coatue Management LLC lifted its position in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. Norges Bank bought a new stake in Natera during the 4th quarter valued at approximately $372,398,000. Finally, JPMorgan Chase & Co. boosted its stake in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on NTRA shares. Wells Fargo & Company lifted their price target on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $375.00 price objective on Natera in a research report on Friday, August 7th. Wolfe Research began coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th. Finally, Stephens upped their target price on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Insiders Place Their Bets

In related news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director directly owned 4,250 shares of the company’s stock, valued at $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 181,045 shares of company stock valued at $41,330,968 in the last ninety days. 5.05% of the stock is currently owned by insiders.

Natera Stock Up 2.2%

Shares of NTRA opened at $332.03 on Friday. The stock’s 50-day moving average price is $274.24 and its 200 day moving average price is $229.39. The firm has a market capitalization of $47.86 billion, a price-to-earnings ratio of -244.14 and a beta of 1.51. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $333.56.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter last year, the company earned ($0.74) EPS. The company’s quarterly revenue was up 37.7% on a year-over-year basis. Equities research analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.